Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 3, 1999, Pages 265-274

  Furuta, Takahisa ^a   Ohashi, Kyoichi ^b   Kobayashi, Kaoru ^b   Iida, Izumi ^b   Yoshida, Hideo ^b   Shirai, Naohito ^b   Takashima, Misako ^b   Kosuge, Kazuhiro ^b   Hanai, Hiroyuki ^b   Chiba, Kan ^b   Ishizaki, Takashi ^b   Kaneko, Eizo ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; 5 HYDROXYOMEPRAZOLE; AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DNA; DRUG METABOLITE; OMEPRAZOLE; OMEPRAZOLE SULFONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; ERADICATION THERAPY; FEMALE; GENOTYPE; HELICOBACTER PYLORI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTEIN SYNTHESIS INHIBITORS; REFERENCE VALUES; VOLUNTARY WORKERS;

EID: 0032843591     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70034-2     Document Type: Article

References (41)

1. 1. Blaser MJ. Hypothesis on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992;102:720-7.
2. 2. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
3. 3. Goodwin CS, Mendall MM, Northfield TC. Helicobacter pylori infection. Lancet 1997;349:265-9.
4. 4. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
5. 5. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: Clinical and economic consequences. Ann Intern Med 1997;126:280-91.
6. 6. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease: practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996;275:622-9.
7. 7. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer diseases. New Engl J Med 1995;333:984-90.
8. 8. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996;1:138-44.
9. 9. al-Assi MT, Cole RA, Karttunen TU, el-Zimaity H, Genta RM, Graham DY. Treatment of Helicobacter pylori infection with omeprazole-amoxicillin combination therapy versus ranitidine/sodium bicarbonate-amoxicillin. Am J Gastroenterol 1995;90:1411-4.
10. 10. Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 1992;29:115-20.
11. 11. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992;11:777-81.
12. 12. Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993;88:1860-4.
13. +-ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
14. +-ATPase: the site of action of omeprazole. Scand J Gastroenterol 1989;166 (suppl):3-11.
15. 2-receptor antagonists. Aliment Pharmacol Ther 1990;4:309-13.
16. 2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106:907-15.
17. 17. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992;262:1195-202.
18. 18. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993;266:52-9.
19. 19. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994;16:214-5.
20. 20. Chang M, Tybring G, Dahl ML, Gøtharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
21. m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-53.
22. 22. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
23. 23. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;49:198-207.
24. 24. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994;269:15419-22.
25. 25. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
26. 26. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999;65:552-61.
27. 27. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129: 1027-30.
28. 28. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994;37:597-604.
29. 29. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsome: major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997;25:623-30.
30. 30. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996;60:661-6.
31. 31. Kobayashi K, Chiba K, Sohn DR, Kato Y, Ishizaki T. Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. J Chromatogr 1992;579:299-305.
32. 32. Labenz J, Stolte M, Blum AL, Jorias I, Leverkus F, Sollbohmer M, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995;37:39-43.
33. 33. Mannes GA, Bayerdorffer E, Hele C, Ruckdeschel G, Stolte M. An increasing dose of omeprazole combined with amoxicillin increases the eradication rate of Helicobacter pylori [abstract]. Gastroenterology 1993;104:A140.
34. 34. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-7.
35. 35. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC. Cancer after exposure to metronidazole. Mayo Clin Proc 1988;63:147-53.
36. 36. Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunaga T, et al. Direct evidence for anti-pseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996;40:2271-5.
37. 37. Uemura N, Okamoto S, Mukai T, Yamaguchi S, Kaji M, Hrruma K, et al. Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin. Eur J Gastroenterol Hepatol 1995;7(suppl 1):S67-9.
38. 38. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
39. 39. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989;8:888-9.
40. 40. Midolo PD, Turnidge JD, Lambert JR, Bell JM. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob Agents Chemother 1996;40:1531-3.
41. 41. Flockhart DA. Drug interactions and the cytochrome P450 system. Clin Pharmacokinet 1995;29(suppl 1):45-52. (Clin Pharmacol Ther 1999;66:275-81.)